AbbVie's Psoriatic Arthritis Treatment SKYRIZI Approved by Health Canada
March 17 2022 - 1:02PM
Dow Jones News
By Denny Jacob
AbbVie Inc., a research-based biopharmaceutical company, said
Thursday that Health Canada approved SKYRIZI, a treatment for
adults with active psoriatic arthritis.
In April 2019, Health Canada approved SKYRIZI for adults with
moderate to severe plaque psoriasis who are candidates for systemic
therapy or phototherapy.
Psoriatic arthritis is an inflammatory disease that typically
manifests in the skin and joints.
AbbVie shares are up 50% to $157.78 in the past 12 months.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 17, 2022 12:47 ET (16:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
